* Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million * H...
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of g...
* The deal enables CStone to prioritize its resources to focus on the development of first-in-clas...
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination...
* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and co...
* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or r...
* The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of ph...
* The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer mar...
* The total revenue for 2022 was RMB 481.4 million, with commercial revenue of RMB 394.1 million, ...
* This supplementary new drug application was filed for the fourth indication for sugemalimab inC...
* Sugemalimab became the first anti-PD-L1 monoclonal antibody that achieved positive results in th...
* This is the third supplemental new drug application (NDA) that CStone has submitted for sugemal...
SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...
* GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addit...
* GAVRETO is the first highly selective rearranged during transfection (RET) inhibitor approved i...
* Sugemalimab is the world's first PD-L1 monoclonal antibody to show the statistically significan...
* The National Medical Products Administration approved sugemalimab for the treatment of patients...
* The National Medical Products Administration approved sugemalimab for the treatment of patients...
* Nofazinlimab in combination with lenvatinib as first-line treatment for unresectable hepatocell...
* GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported ...